

# JPMorgan Funds - US Research Enhanced Index Equity Fund

JPM X (acc) - USD


April 2015

## Fund overview

### Investment objective

To achieve a long-term return in excess of the benchmark by investing primarily in a portfolio of US companies; the risk characteristics of the portfolio of securities held by the Sub-Fund will resemble the risk characteristics of the portfolio of securities held in the benchmark.

### Morningstar style box <sup>®</sup> <sup>A</sup>



## Fund statistics

Morningstar Category <sup>TM</sup>	US Large-Cap Blend Equity
Fund manager(s)	Raffaele Zingone, Tim Snyder
Client portfolio manager(s)	Christian Preussner, Fiona Harris
Fund launch date	18/02/11
Fund size (as at 30/04/15)	USD 616.6m
NAV (as at 30/04/15)	103.32
12M NAV High (as at 27/04/15)	105.04
12M NAV Low (as at 16/01/15)	98.16
Share class launch date <sup>B</sup>	12/01/15

## Fund codes

ISIN	LU1163232579
Bloomberg	JUSRXUS LX
Reuters	LU1163232579.LUF

## Quarterly comments

(as at 31/03/15)

### Review

US equity markets were a virtual seesaw in the first quarter. While the S&P 500 Index reached an all-time high on 2 March, it experienced three mini dips of greater than 3%. Investor concerns were largely focused on reduced earnings estimates caused by the massive decline in oil prices and the continued strength of the US dollar.

The fund underperformed the benchmark. Our stock selection in the industrial cyclical and media sectors proved detrimental. On the other hand, our stock selection in the semiconductors and pharmaceuticals and medtech sectors added value.

In the industrial cyclical sector, our lack of exposure to Boeing was one of the major detractors. Our overweight position in Paccar also hurt as investors were concerned that the North American truck cycle might have reached its peak.

In contrast, our overweight positions in the semiconductor name Avago Technologies and Boston Scientific in the pharmaceuticals and medtech sector helped. The semiconductor company got a boost from its fourth-quarter earnings report. Boston Scientific surged following the FDA approval of its second-generation Watchman stroke-prevention device.

### Outlook

Despite the volatility we have seen so far this year, our outlook for both the US economy and equity markets remains constructive. We believe markets will be more volatile than they have been in the past few years given that equities are now fairly valued. However, given that the bottom-line benefits of lower energy prices have not been considered and the European economy continues to improve, estimates may in fact rise as the year progresses.


## Benchmark

S&P 500 Index (Total Return Net of 30% withholding tax)


## Performance

(as at 30/04/15)

### Cumulative performance



### Calendar year performance



## Cumulative performance

%	1 M	3 M	1 Y	3 Y	5 Y	10 Y
JPM X (acc) - USD	-	-	-	-	-	-

## Calendar year performance

	2011	2012	2013	2014	YTD
JPM X (acc) - USD	-	-	-	-	-

## Annualised performance

%	1 Y	3 Y	5 Y	Since inception
JPM X (acc) - USD	-	-	-	-

# JPMorgan Funds - US Research Enhanced Index Equity Fund

## Fund facts

### Fund charges

Initial charge (max.)	0.00%
Redemption charge (max.)	0.00%
Annual Mgt.	0.00%
Distribution Fee	0.00%
Expenses	0.15%
TER (Total Expense Ratio)	0.15%

### Statistical analysis review

(as at 30/04/15)

	3 years	5 years
Correlation	-	-
Alpha	-	-
Beta	-	-
Annualised volatility	-	-
Sharpe ratio	-	-
Information ratio	-	-

## Holdings

### 10 largest holdings

(as at 30/04/15)

Equity holding	Weight
Apple (Systems & Network Hardware)	4.1%
Microsoft (Software & Services)	2.7%
Wells Fargo (Banks & Brokers)	2.4%
Google (Media)	2.0%
Exxon Mobil (Energy)	1.6%
United Technologies (Industrial Cyclical)	1.5%
Johnson & Johnson (Pharm/MedTech)	1.5%
Citigroup (Banks & Brokers)	1.5%
Verizon Communications (Telecommunications)	1.5%
Facebook (Media)	1.5%

## Investor suitability

### Investor profile

This Sub-Fund is designed to give broad market exposure to the US stock market. This Sub-Fund may be suitable for investors who seek to benefit from potential excess returns with similar risks to investing in securities representing the benchmark. The Sub-Fund is managed conservatively relative to the benchmark and may be suitable for investors who are looking for a core US equity investment, or as a standalone investment aimed at producing long-term capital growth. Investors in this Sub-Fund should have a three to five year investment horizon.

### Key risks

The value of your investment may fall as well as rise and you may get back less than you originally invested.

The Sub-Fund seeks to provide a return above the benchmark; however the Sub-Fund may underperform its benchmark.

The value of equity securities may go down as well as up in response to the performance of individual companies and general market conditions.

The single market in which the Sub-Fund invests may be subject to particular political and economic risks, and as a result, the Sub-Fund may be more volatile than more broadly diversified funds.

### Sector breakdown

(as at 30/04/15)

Sector	Fund	Benchmark	Deviation
Pharm/MedTech	11.7%	11.8%	-0.1%
Industrial Cyclical	11.1%	11.1%	0.0%
Energy	7.8%	7.7%	0.1%
Banks & Brokers	7.5%	7.4%	0.1%
Consumer Stable	7.2%	7.0%	0.2%
Media	7.1%	7.1%	0.0%
Software & Services	6.7%	6.4%	0.3%
Retail	6.6%	6.6%	0.0%
Systems & Network Hardware	5.3%	5.9%	-0.6%
Telecommunications	3.9%	4.0%	-0.1%
Health Services & Systems	3.8%	3.7%	0.1%
Utilities	3.7%	3.8%	-0.1%
Financial Services	3.4%	3.4%	0.0%
Basic Materials	3.3%	3.3%	0.0%
Semiconductors	3.2%	3.1%	0.1%
Consumer Cyclical	2.8%	2.8%	0.0%
Insurance	2.8%	2.7%	0.1%
REITs	2.1%	2.2%	-0.1%
Total	100.0%	100.0%	0.0%

# JPMorgan Funds - US Research Enhanced Index Equity Fund

## Explanatory Notes, Risks and Important Information

### Notes

<sup>A</sup>The Morningstar Style Box <sup>™</sup> indicates the fund's investment strategy. For equity funds the vertical axis shows the capitalization of the shares held by the fund, and the horizontal axis shows investment style (value, mixed, or growth). In bond funds, the vertical axis shows the average risk quality of the bonds the fund owns, and the horizontal axis indicates sensitivity to interest rates, as measured by the duration of the bond (short, medium, or long).

<sup>B</sup>For reactivated share classes the performance is shown from the date of reactivation and not the share class launch date.

All equity indices stated as 'Net' are calculated net of tax as per the standard published approach by the index vendor unless stated otherwise.

You should remember that past performance is not a guide to the future. The price of investments and the income from them may fall as well as rise and investors may not get back the full amount invested.

All performance details are NAV - NAV with gross income reinvested.

FX Adjusted returns have been calculated by JPMAM. Blended benchmarks have been calculated by JPMAM.

Source: J.P. Morgan

### Important Information

This is a promotional document and as such the views contained herein are not to be taken as an advice or recommendation to buy or sell any investment or interest thereto. Reliance upon information in this material is at the sole discretion of the reader. Any research in this document has been obtained and may have been acted upon by J.P. Morgan Asset Management for its own purpose. The results of such research are being made available as additional information and do not necessarily reflect the views of J.P. Morgan Asset Management. Any forecasts, figures, opinions, statements of financial market trends or investment techniques and strategies expressed are unless otherwise stated, J.P. Morgan Asset Management's own at the date of this document. They are considered to be reliable at the time of writing, may not necessarily be all-inclusive and are not guaranteed as to accuracy. They may be subject to change without reference or notification to you.

It should be noted that the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Changes in exchange rates may have an adverse effect on the value, price or income of the product(s) or underlying overseas investments. Both past performance and yield may not be a reliable guide to future performance. There is no guarantee that any forecast made will come to pass. Furthermore, whilst it is the intention to achieve the investment objective of the investment product(s), there can be no assurance that those objectives will be met.

J.P. Morgan Asset Management is the brand name for the asset management business of JPMorgan Chase & Co and its affiliates worldwide. You should note that if you contact J.P. Morgan Asset Management by telephone those lines may be recorded and monitored for legal, security and training purposes. You should also take note that information and data from communications with you will be collected, stored and processed by J.P. Morgan Asset Management in accordance with the EMEA Privacy Policy which can be accessed through the following website <http://www.jpmorgan.com/pages/privacy>.

As the product may not be authorised or its offering may be restricted in your jurisdiction, it is the responsibility of every reader to satisfy himself as to the full observance of the laws and regulations of the relevant jurisdiction. Prior to any application investors are advised to take all necessary legal, regulatory and tax advice on the consequences of an investment in the product(s). Shares or other interests may not be offered to or purchased directly or indirectly by US persons. All transactions should be based on the latest available prospectus, the Key Investor Information Document (KIID) and any applicable local offering document. These documents together with the annual report, semi-annual report and the articles of incorporation for the Luxembourg domiciled product(s) are available free of charge upon request from JPMorgan Asset Management (Europe) S.à.r.l., 6 route de Trèves, L-2633 Senningerberg, Grand Duchy of Luxembourg, your financial adviser or your J.P. Morgan Asset Management regional contact. In Switzerland, J.P. Morgan (Suisse) SA, 8, rue de la Confédération, PO Box 5507, 1211 Geneva 11, Switzerland, has been authorised by the Swiss Financial Market Supervisory Authority FINMA as Swiss representative and as paying agent of the funds.

Morningstar Ratings <sup>™</sup>: © Morningstar. All Rights Reserved.